Andritz is well positioned to win upcoming major pulp mill projects (42% Pulp & Paper sales share in 2024), which should raise sales to the targeted level of € 9-10bn for 2027e and trigger a revaluation of the share. The group’s high-margin service business should continue to grow and support an increase in the comparable EBITA margin to over 9% by 2027e (vs 8.9% in 2024). The higher group order intake in Q4 2024 (+27% vs css) confirms the improved business sentiment in all segments. With its as...
EME Equity Market – March 2025 Türkiye hammered, once again. The MSCI EM Europe Index advanced 0.5% in EUR terms and 4.5% mom in USD terms in March. The Czech PX Index was the best performer (+7.0% mom in EUR terms), followed by the Greek ASE (+4.8% mom), Polish WIG (+3.7% mom) and Hungarian BUX(+1.3% mom) indices (all in EUR terms). There was a muted performance from the Romanian BET Index (-0.1% mom in EUR terms). The Turkish ISE30 finished in the red again, declining 9.5% mom in EUR terms.
HEADLINES: • Athens Exchange Group: bottom-line miss in 4Q24, on higher costs, but proposed DPS in line with expectations NEUTRAL • AROBS Transilvania Software: publishes its 2025 budget POSITIVE • MedLife: publishes its 2025 budget NEGATIVE • CCC: new financing agreement, extending factoring line POSITIVE • DataWalk: sale to Coöperatieve Rabobank; total contract value reaches PLN 66.1m POSITIVE • Orlen: 2024 consolidated results to be affected by one-offs NEUTRAL • Poland macro: preliminary Mar...
HEADLINES: • Benefit Systems: pumping iron (stays BUY) • Jeronimo Martins: small beat in 4Q24, Biedronka margin erosion slows down; tough market environment continues in 2025 POSITIVE • OPAP: the beat goes on, in 4Q24 POSITIVE • Tauron: preliminary 4Q24 EBITDA 45% above our estimate, on strong Generation and Distribution, and lower loss in Supply POSITIVE • Türkiye macro: assessment of recent political events • Allegro vs. InPost: our take on the companies' two calls • cyber_Folks / Shoper: key ...
A director at Med Life SA sold 1,000,000 shares at 5.800RON and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
EQS-News: Andritz AG / Key word(s): Annual Results ANDRITZ reports satisfactory results for 2024 06.03.2025 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Strong order intake in Q4 brings book-to-bill ratio to 1 Revenue declined slightly by 4%, EBITA margin remained stable Net income margin increased to 6%, reaching 2026 target prematurely Increase in dividends to 2.60 EUR per share GRAZ, MARCH 6, 2025. Despite a continuously challenging market environment, international technology group ANDRITZ achieved satisfactory results in ...
EQS-News: Andritz AG / Schlagwort(e): Jahresergebnis ANDRITZ meldet zufriedenstellende Ergebnisse für 2024 06.03.2025 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Starker Auftragseingang im vierten Quartal bringt Book-to-Bill-Ratio auf 1 Umsatz leicht rückläufig um 4%, EBITA-Marge stabil Steigerung der Konzernergebnis-Marge auf 6%, Ziel für 2026 vorzeitig erreicht Erhöhung der Dividende auf 2,60 EUR je Aktie GRAZ, 6. MÄRZ 2025. Der internationale Technologiekonzern ANDRITZ erzielte im Geschäftsjahr 2024 trotz eines weite...
HEADLINES: • MedLife: and let the operational gearing begin (upgraded to BUY) • Enea: preliminary 4Q24 results broadly in line with expectations NEUTRAL • Elm: 4Q24 conference call takeaways • 4iG: 4Q24 earnings call takeaways NEUTRAL • Türkiye macro: February inflation performs better than the CBT’s projections • OMV: agrees on Borealis, Borouge and Nova chemicals deal with ADNOC POSITIVE • InPost: extension of available financing to PLN 4.2bn, from PLN 2.8bn POSITIVE • Wizz Air: February capac...
Following the 4Q24 earnings release, we have updated our 12M price target for MedLife to RON 7.1/share and upgraded our rating from Hold to BUY, with upside of c.20%. Last year was the inflection point for the EBITDA, growing 36% yoy. Below the EBITDA, these gains were largely offset by higher depreciation, interest expense and taxes; only c.20% of the upside made it to the bottom line. We expect that to reverse this year, on: 1) more modest growth in depreciation and taxes; and 2) a c.20% drop ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.